StockNews.AI
QGEN
StockNews.AI
216 days

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

1. QIAGEN will release Q4 2024 results on February 5, 2025. 2. Conference call scheduled for February 6 at 16:00 Frankfurt time. 3. QIAGEN provides solutions in Molecular Diagnostics and Life Sciences globally. 4. The company aims to deliver insights from complex biological samples. 5. As of September 2024, QIAGEN has over 5,800 employees.

Earnings
+0.7%Current Return
VS
+1.82%S&P 500
$45.5701/15 09:00 AM EDTEvent Start
$45.8901/16 03:37 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements typically have mixed effects but depend on actual performance.

How important is it?

Earnings results directly influence stock movement and investor sentiment.

Why Short Term?

The results may lead to immediate market reactions but are short-lived.

Related Companies

QGEN
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024. Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 646 828 8193 UK: +44 (0)330 165 4027 GER: +49 (0)69 6610 2480 Conference ID: 9237018 To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. Access the audio webcast - Click here: Access Webcast A conference call replay will be available by using the following link: https://event.webcasts.com/starthere.jsp?ei=1684130&tp_key=c56f1d6ba2 Contact: IR@qiagen.com About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com. Source: QIAGEN N.V. Category: Financial

Related News